{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T03:55:50Z","timestamp":1795146950736,"version":"4.10.3"},"reference-count":19,"publisher":null,"issue":"11","license":[{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>\n                    <jats:italic>Aim<\/jats:italic>\n                    \u00a0\u00a0\u00a0\u00a0\u00a0 To evaluate 5-year results of the HREVS (Hybrid REvascularization Versus Standarts) study.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Material and methods<\/jats:italic>\n                    \u00a0 The study included 155 consecutive patients with multivessel coronary artery disease who were randomized into 3 groups: coronary artery bypass grafting (CABG) (n=50), hybrid coronary revascularization (HCR) (n=52) and percutaneous coronary intervention (PCI) (n=53) according to the consensus of the cardiology team on the technical and clinical feasibility of each of the three coronary revascularization strategies. The primary endpoint of the study was residual ischemia 12 months after revascularization according to data of single-photon emission computed tomography (SPECT). Secondary endpoints were major adverse cardiac and cerebrovascular events (MACCE) over 5 years of follow-up, which included all-cause death, myocardial infarction, stroke, and clinically determined repeat myocardial revascularization.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results<\/jats:italic>\n                    Baseline characteristics of patients did not differ between study groups. Median residual ischemia determined by SPECT data after 12 months was not statistically significantly different in the CABG, HCR and PCI groups: 6.7 [4.6; 8.8]%, 6.4 [4.3; 8.5]% and 7.9 [5.9; 9.8]%, respectively (p=0.45). Mean follow-up period was 76.5 months (at least 60 months). There were no statistically significant differences in all-cause mortality between the CABG, HCR and PCI groups, 10.6, 12.8 and 8.2\u200a%, respectively (p=0.23). Statistically significant differences between the groups of CABG, HCR and PCI in the incidence of myocardial infarction (12.8; 8.5 and 16.3\u200a%; p=0.12), stroke (4.2; 6.4 and 10.2\u200a% ; p=0.13), repeat revascularization for clinical indications (23.4; 23.4 and 34.7\u200a%; p=0.11) were not observed either. However, the cumulative 5-year MACCE value was similar in the HCR group and the CABG group but significantly lower than in the PCI group (51.1, 51.1 and 69.4\u200a%, respectively; p = 0.03).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion<\/jats:italic>\n                    \u00a0\u00a0\u00a0\u00a0\u00a0 HCR that combines advantages of PCI and CABG is a promising strategy for coronary revascularization in multivessel coronary artery disease. HCR demonstrates satisfactory long-term results comparable to those of CABG but superior to PCI. To confirm the safety and efficacy of HCR, a large multicenter study is required that would have a sufficient power to evaluate clinical endpoints.\n                  <\/jats:p>\n                  <jats:p>\u00a0<\/jats:p>","DOI":"10.18087\/cardio.2023.11.n2475","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T09:45:13Z","timestamp":1702374313000},"page":"57-63","source":"Crossref","is-referenced-by-count":12,"title":["Randomized Clinical Trial of Hybrid vs. Surgical vs. Percutaneous Multivessel Coronary Revascularization: 5\u2011year Follow-up of HREVS Trial"],"prefix":"10.68900","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9704-7678","authenticated-orcid":true,"given":"V. I.","family":"Ganyukov","sequence":"first","affiliation":[{"name":"\"Scientific Research Institute of Complex Problems of Cardiovascular Diseases\", Kemerovo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. A.","family":"Kochergin","sequence":"additional","affiliation":[{"name":"\"Scientific Research Institute of Complex Problems of Cardiovascular Diseases\", Kemerovo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4194-6623","authenticated-orcid":true,"given":"A. A.","family":"Shilov","sequence":"additional","affiliation":[{"name":"\"Scientific Research Institute of Complex Problems of Cardiovascular Diseases\", Kemerovo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. S.","family":"Tarasov","sequence":"additional","affiliation":[{"name":"\"Scientific Research Institute of Complex Problems of Cardiovascular Diseases\", Kemerovo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. A.","family":"Kozyrin","sequence":"additional","affiliation":[{"name":"\"Scientific Research Institute of Complex Problems of Cardiovascular Diseases\", Kemerovo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. S.","family":"Prokudina","sequence":"additional","affiliation":[{"name":"\"Scientific Research Institute of Complex Problems of Cardiovascular Diseases\", Kemerovo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. L.","family":"Barbarash","sequence":"additional","affiliation":[{"name":"\"Scientific Research Institute of Complex Problems of Cardiovascular Diseases\", Kemerovo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. S.","family":"Barbarash","sequence":"additional","affiliation":[{"name":"\"Scientific Research Institute of Complex Problems of Cardiovascular Diseases\", Kemerovo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2023,12,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Sardar P, Kundu A, Bischoff M, et al. Hybrid coronary revascularization versus coronary artery bypass grafting in patients with multivessel coronary artery disease: a meta-analysis. Catheter Cardiovasc Interv 2018;91:203\u201312. doi: 10.1002\/ccd.27098","DOI":"10.1002\/ccd.27098"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A, et al. \u201c2018 ESC\/EACTS Guidelines on myocardial revascularization\u201d. European Heart Journal, vol. 40, no 2, pp. 87-165, 2019. doi: 10.1093\/eurheartj\/ehy394","DOI":"10.1093\/eurheartj\/ehy855"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Phan K, Wong S, Wang N, Phan S, Yan TD. Hybrid coronary revascularization versus coronary artery bypass surgery: systematic review and meta-analysis. Int J Cardiol 2015;179:484\u20138. doi: 10.1016\/j.ijcard.2014.11.061","DOI":"10.1016\/j.ijcard.2014.11.061"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Habib RH, Dimitrova KR, Badour SA, et al. \u201cCABG Versus PCI: Greater benefit in long-term outcomes with multiple arterial bypass grafting\u201d.  J Am Coll Cardiol, vol. 66, no 13, pp. 1417-27, 2015. doi: 10.1016\/j.jacc.2015.07.060","DOI":"10.1016\/j.jacc.2015.07.060"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Bangalore S, Guo Y, Samadashvili Z, et al. \u201cEverolimus-eluting stents or bypass surgery for multivessel coronary disease\u201d.  N Engl J Med. vol. 372, no 13, pp. 1213-22, 2015. doi: 10.1056\/NEJMoa1412168","DOI":"10.1056\/NEJMoa1412168"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Park SJ, Ahn JM, Kim YH, et al. \u201cTrial of everolimus-eluting stents or bypass surgery for coronary disease\u201d.  N Engl J Med, vol. 372, No 13, pp. 1204-12, 2015. doi: 10.1056\/NEJMoa1415447","DOI":"10.1056\/NEJMoa1415447"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Panoulas VF, Colombo A, Margonato A, Maisano F. \u201cHybrid coronary revascularization: Promising, but yet to take off\u201d.  J Am Coll Cardiol, vol. 65, no 1, pp. 85-97, 2015. doi: 10.1016\/j.jacc.2014.04.093","DOI":"10.1016\/j.jacc.2014.04.093"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Diegeler A. \u201cHybrid Coronary Revascularization: The Best of 2 Worlds?\u201d  J Am Coll Cardiol, vol. 68, no 4, pp. 366-7, 2016. doi: 10.1016\/j.jacc.2016.05.029","DOI":"10.1016\/j.jacc.2016.05.029"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Giambruno V, Hafiz A, Fox SA, et al. \u201cIs the future of coronary arterial revascularization a hybrid approach? The Canadian experience across three centers\u201d.  Innovations, vol. 12, no 2, pp. 82-86, 2017. doi: 10.1097\/IMI.0000000000000355","DOI":"10.1177\/155698451701200202"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Sardar P, Kundu A, Bischoff M, et al. \u201cHybrid coronary revascularization versus coronary artery bypass grafting in patients with multivessel coronary artery disease: A meta-analysis\u201d.  Catheter Cardiovasc Interv, vol. 91, no 2, pp. 203-212, 2018. doi: 10.1002\/ccd.27098","DOI":"10.1002\/ccd.27098"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Puskas JD, Halkos ME, DeRose JJ, et al.  \u201dHybrid Coronary Revascularization for the Treatment of Multivessel Coronary Artery Disease: A Multicenter Observational Study\u201d.  J Am Coll Cardiol,  vol. 68, no 4, pp. 356-65, 2016. doi: 10.1016\/j.jacc.2016.05.032","DOI":"10.1016\/j.jacc.2016.05.032"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Ganyukov V.I., Kochergin N.A., Shilov A.A., et al. Randomized clinical trial of surgical versus percutaneous versus hybrid multivessel coronary revascularization: 3 years\u2019 follow-up. JACC: Cardiovascular Interventions. 2021. \u0422. 14. \u2116 10. \u0421. 1163-1165. doi: 10.1016\/j.jcin.2021.02.037","DOI":"10.1016\/j.jcin.2021.02.037"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Ganyukov V, Kochergin N, Shilov A, Tarasov R, Skupien J, Szot W, Kokov A, Popov V, Kozyrin K, Barbarash O, Barbarash L, Musialek P. Randomized Clinical Trial of Surgical vs. Percutaneous vs. Hybrid Revascularization in Multivessel Coronary Artery Disease: Residual Myocardial Ischemia and Clinical Outcomes at One Year-Hybrid coronary REvascularization Versus Stenting or Surgery (HREVS). J Interv Cardiol. 2020 Jan 3;2020:5458064. doi: 10.1155\/2020\/5458064","DOI":"10.1155\/2020\/5458064"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Thygesen K, Alpert JS, Jaffe AS, et al. \u201cFourth universal definition of myocardial infarction\u201d. Circulation, 2018; 138(20):e618-e651. doi: 10.1161\/CIR.0000000000000617.","DOI":"10.1161\/CIR.0000000000000617"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Sacco RL, Kasner SE, Broderick JP, et al. \u201cAn updated definition of stroke for the 21st century: A statement for healthcare professionals from the American Heart Association\/American Stroke Association\u201d. Stroke, 2013;44:2064\u20132089. doi:10.1161\/STR.0b013e318296aeca","DOI":"10.1161\/STR.0b013e318296aeca"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Wu S, Ling Y, Fu Y, et al. \u201cMid-term follow-up outcomes of 2-staged hybrid coronary revascularization compared with off-pump coronary artery bypass for patients with multivessel coronary artery disease\u201d.  Wideochir Inne Tech Maloinwazyjne, vol. 12, no 2, pp. 178-185, 2017. doi: 10.5114\/wiitm.2017.66803","DOI":"10.5114\/wiitm.2017.66803"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Taggart DP, Altman DG, Flather M, et al. \u201cAssociations between adding a radial artery graft to single and bilateral internal thoracic artery grafts and outcomes: Insights from the arterial revascularization trial\u201d.  Circulation, vol.136, no 5, pp. 454-463, 2017. DOI: 10.1161\/circulationaha.117.027659","DOI":"10.1161\/CIRCULATIONAHA.117.027659"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"M. Tajstra, T. Hrapkowicz, M. Hawranek, K. Filipiak, M. Gierlotk, M. Zembala, M. Gasior, M.O. Zembal, POL-MIDES Study Investigators. Hybrid Coronary Revascularization in Selected Patients with Multivessel Disease: 5-Year Clinical Outcomes of the Prospective Randomized Pilot Study. JACC Cardiovasc Interv. 2018 May 14;11(9):847-852. doi: 10.1016\/j.jcin.2018.01.271","DOI":"10.1093\/eurheartj\/ehy565.1465"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Moreno PR, Stone GW, Gonzalez-Lengua CA, Puskas JD. The Hybrid Coronary Approach for Optimal Revascularization: JACC Review Topic of the Week. J Am Coll Cardiol 2020 Jul 21;76(3):321-333. doi: 10.1016\/j.jacc.2020.04.078","DOI":"10.1016\/j.jacc.2020.04.078"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/2475\/1468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:16:32Z","timestamp":1793639792000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/2475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,12,11]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2023.11.n2475","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,5]]}}}